Cipla Offers India Government Knowledge To Make Important Drugs
This article was originally published in PharmAsia News
Cipla announced it would share with colleagues and competitors its technological knowledge about drug making as it concerns 354 drugs considered essential in India. The offer was made to discourage the government from imposing price controls on selective brands and generics. Managing Director Amar Lulla said Cipla would share its knowledge with the state-owned drug maker so the drugs could be distributed by the government through primary health care centers, medical hospitals and public health institutions at reasonable prices. Cipla has not signed on to a separate industry proposal to the government. (Click here for more
You may also be interested in...
Concern and skepticism about Russia's rapid vaccine roll-out. Meanwhile Japan is latest to reach reaches deal with Pfizer/BioNTech.
Sun’s Q1 earnings were dented by provisions related to the generic pricing investigation settlement with the US Department of Justice of arm Taro, and the impact of pandemic-related lockdowns. Some clinic-administered products bore the brunt of lock-downs in parts of the US, though market share was unaffected.
Diabetes company Dexcom said it expects 2020 revenues to reach $1.85bn driven by new patient adoption of its continuous glucose monitoring (CGM) system including by people with type 2 diabetes. See what SVB Leerink analyst Danielle Antalffy said about Dexcom’s earnings results here.